Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

Safety and Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stem Cell Transplantation in Acute Lung Injury

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study.

Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects.

The day of infusion will be considered day zero. From that moment, followup will be divided into 2,7,14 days.

Clinical results will be analyzed after completion of 14 days of followup.

Inclusion Criteria:

• Signed informed consent
• Age between 35 and 70 y
• Acute onset within 7 days.
• Oxygenation index:200<PaO2/FiO2≤300mmHg; alveolar-arterial oxygen differences:P(A-a)O2>35mmHg
• Bilateral infiltrates on chest radiography
• No cardiac failure

Exclusion Criteria:

• Declined to sign informed consent
• Socially and mentally disabilities
• Malignant diseases
• Combined with severe infectious diseases
• Patients with positive blood tests for Hepatitis B or Hepatitis C or HIV or tuberculosis at the time of screening
• Pregnant or perinatal women
• Severe diseases of any major organs